Time to first relapse
Fig. 3 · Panel Time_to_first_relapse
Panel Time_to_first_relapse 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Marta Simone, Roberto Palumbi, Mariaclara Achille, Stefania Micella, Mara Pascali, Antonia Peschechera, Alessandra Gabellone, Lucia Marzulli, Andrea De Giacomo, Giulia Maggi, Giorgio Reggiardo, Mariagrazia Felisi, Rosa Padula, Donato Bonifazi, Massimiliano Valeriani, Laura Papetti, Roberta Lanzillo, Valentina Torri Clerici, Lucia Margari
Neurol Sci 46(10) 5391-5400
BACKGROUND: Paediatric-onset Multiple Sclerosis (POMS) is a rare, highly active disease requiring timely disease-modifying therapy. OBJECTIVES: This trial compared the efficacy and safety of intramuscular (i.m.) Interferon beta-1a (IFN-beta 1a) and subcutaneous (s.c.) Glatiramer Acetate (GA). METHODS: A 96-week, Phase IIIb, multicenter, open-label randomized trial enrolled 30 participants (ages 12-17). Patients were randomized into two groups: 15 received i.m. IFN-beta 1a, and 15 received s.c. GA. The primary endpoint was MRI disease activity-free status; secondary outcomes included annualized relapse rate (ARR), time to first relapse, Expanded Disability Status Scale (EDSS), cognitive and fatigue scores, and quality of life. RESULTS: The groups differed by age but not sex. MRI disease activity-free status did not differ (p = 0.09). ARR was significantly lower in the GA group (0.20; 95% CI 0.08-0.42) than in the IFN-beta 1a group (0.57; 95% CI 0.31-0.95, p = 0.02). EDSS, cognitive, fatigue, and quality-of-life scores were comparable. Notably, 50% of GA patients and 30% of IFN-beta 1a patients switched to higher efficacy treatments. CONCLUSIONS: Both treatments showed similar efficacy and safety, but early high-efficacy therapy may be preferable for POMS management. TRIAL REGISTRATION: EudraCT Number: 2017-005129-18. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005129-18/IT.
2 个 Figure · 2 个 KM 面板
Fig. 3 Time to first relapse, assessed through Kaplan–Meier curves
Fig. 3 · Panel Time_to_first_relapse
Panel Time_to_first_relapse 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Cumulative survival function (event = treatment switch)
Fig. 4 · Panel Cumulative_survival_function_event_treatment_switch_
Panel Cumulative_survival_function_event_treatment_switch_ 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。